Science Board Advisory Committee; Notice of Meeting, 65497-65498 [2010-26828]
Download as PDF
Federal Register / Vol. 75, No. 205 / Monday, October 25, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Neurodegeneration Special Emphasis Panel.
Date: October 28, 2010.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: Carole L. Jelsema, PhD,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176,
MSC 7850, Bethesda, MD 20892. (301) 435–
1248. jelsemac@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Blueprint
Neurotherapeutics.
Date: December 2, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Palomar, 2121 P Street, NW.,
Washington, DC 20037.
Contact Person: Ernest W. Lyons, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS, Neuroscience
Center, 6001 Executive Blvd., Room 3208,
MSC 9529, Bethesda, MD 20892–9529. 301–
496–4056. lyonse@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: October 18, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–26932 Filed 10–22–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Dated: October 19, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Science Board Advisory Committee;
Notice of Meeting
[FR Doc. 2010–26935 Filed 10–22–10; 8:45 am]
HHS.
BILLING CODE 4140–01–P
ACTION:
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
emcdonald on DSK2BSOYB1PROD with NOTICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
VerDate Mar<15>2010
16:05 Oct 22, 2010
Jkt 223001
Food and Drug Administration,
Notice of meeting.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Science Board to
the Food and Drug Administration
(Science Board).
General Function of the Committee:
The Science Board provides advice
primarily to the Commissioner of Food
and Drugs and other appropriate
officials on specific complex and
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
65497
technical issues, as well as emerging
issues within the scientific community
in industry and academia. Additionally,
the Science Board provides advice to
the agency on keeping pace with
technical and scientific evolutions in
the fields of regulatory science, on
formulating an appropriate research
agenda, and on upgrading its scientific
and research facilities to keep pace with
these changes. It will also provide the
means for critical review of agency
sponsored intramural and extramural
scientific research programs.
DATES: Date and Time: The meeting
will be held on Monday, November 15,
2010, from 8:30 a.m. to 4 p.m.
ADDRESSES: Bethesda Marriott, 5151
Pooks Hill Rd., Bethesda, MD 20814.
Contact Person: Martha Monser,
Office of the Commissioner, Food and
Drug Administration, WO Bldg. 32, rm.
4286, 10903 New Hampshire Ave.,
Silver Spring, MD 20993–0002, 301–
796–4627, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 301–451–2603. Please call
the Information Line for up-to-date
information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
agency’s Web site and call the
appropriate advisory committee hot
line/phone line to learn about possible
modifications before coming to the
meeting.
Agenda: The Science Board will
receive information from the ongoing
review of the Pharmacovigilance
Program at the Center for Drug
Evaluation and Research (CDER). The
Center for Food Safety and Applied
Nutrition (CFSAN) will present its
evaluation and review of the final report
of the CFSAN Research Review
Subcommittee of the Science Board to
the Food and Drug Administration and
provide an overview of its strategic
plan. New information and updates will
be provided concerning FDA’s activities
in support of Comparative Effectiveness
Research. In addition, the Board will be
provided with updates on the
development and broad priorities of
FDA’s Strategic Science Plan, and the
FDA Medical Countermeasures
Initiative, including planning for its
regulatory science component.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
E:\FR\FM\25OCN1.SGM
25OCN1
emcdonald on DSK2BSOYB1PROD with NOTICES
65498
Federal Register / Vol. 75, No. 205 / Monday, October 25, 2010 / Notices
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before Monday, November
8, 2010. Oral presentations from the
public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before Friday,
October 29, 2010. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by Monday, November
1, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Martha
Monser, at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committee/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
VerDate Mar<15>2010
16:05 Oct 22, 2010
Jkt 223001
Dated: October 15, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2010–26828 Filed 10–22–10; 8:45 am]
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Alternative Medicine; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel, Type 3 P01s.
Date: November 16, 2010.
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call.)
Contact Person: Peter Kozel, PhD,
Scientific Review Officer, NCCAM, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892–5475. 301–496–8004.
kozelp@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: October 15, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–26907 Filed 10–22–10; 8:45 am]
Frm 00053
Fmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Career Enhancement Awards for Stem Cell
Research.
Date: November 10, 2010.
Time: 12:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call.)
Contact Person: William J Johnson, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7178,
Bethesda, MD 20892–7924. 301–435–0725.
johnsonw@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 19, 2010.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–26889 Filed 10–22–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
BILLING CODE 4140–01–P
PO 00000
National Institutes of Health
Sfmt 4703
E:\FR\FM\25OCN1.SGM
25OCN1
Agencies
[Federal Register Volume 75, Number 205 (Monday, October 25, 2010)]
[Notices]
[Pages 65497-65498]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26828]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Science Board Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Science Board to the Food and Drug
Administration (Science Board).
General Function of the Committee: The Science Board provides
advice primarily to the Commissioner of Food and Drugs and other
appropriate officials on specific complex and technical issues, as well
as emerging issues within the scientific community in industry and
academia. Additionally, the Science Board provides advice to the agency
on keeping pace with technical and scientific evolutions in the fields
of regulatory science, on formulating an appropriate research agenda,
and on upgrading its scientific and research facilities to keep pace
with these changes. It will also provide the means for critical review
of agency sponsored intramural and extramural scientific research
programs.
DATES: Date and Time: The meeting will be held on Monday, November 15,
2010, from 8:30 a.m. to 4 p.m.
ADDRESSES: Bethesda Marriott, 5151 Pooks Hill Rd., Bethesda, MD 20814.
Contact Person: Martha Monser, Office of the Commissioner, Food and
Drug Administration, WO Bldg. 32, rm. 4286, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 301-796-4627, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 301-451-2603. Please call the Information Line for up-to-
date information on this meeting. A notice in the Federal Register
about last minute modifications that impact a previously announced
advisory committee meeting cannot always be published quickly enough to
provide timely notice. Therefore, you should always check the agency's
Web site and call the appropriate advisory committee hot line/phone
line to learn about possible modifications before coming to the
meeting.
Agenda: The Science Board will receive information from the ongoing
review of the Pharmacovigilance Program at the Center for Drug
Evaluation and Research (CDER). The Center for Food Safety and Applied
Nutrition (CFSAN) will present its evaluation and review of the final
report of the CFSAN Research Review Subcommittee of the Science Board
to the Food and Drug Administration and provide an overview of its
strategic plan. New information and updates will be provided concerning
FDA's activities in support of Comparative Effectiveness Research. In
addition, the Board will be provided with updates on the development
and broad priorities of FDA's Strategic Science Plan, and the FDA
Medical Countermeasures Initiative, including planning for its
regulatory science component.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the
[[Page 65498]]
meeting, the background material will be made publicly available at the
location of the advisory committee meeting, and the background material
will be posted on FDA's Web site after the meeting. Background material
is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
Monday, November 8, 2010. Oral presentations from the public will be
scheduled between approximately 1 p.m. and 2 p.m. Those desiring to
make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before Friday, October 29, 2010. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by Monday, November 1, 2010.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Martha Monser, at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisory Committee/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 15, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-26828 Filed 10-22-10; 8:45 am]
BILLING CODE 4160-01-P